Company Overview
Krishna Institute of Medical Sciences (KIMS) is a prominent healthcare provider in India, offering a wide range of medical services across various specialties. KIMS is known for its state-of-the-art facilities, experienced medical professionals, and commitment to delivering quality healthcare. With multiple hospitals and centers, KIMS aims to provide accessible and affordable healthcare services to the community.
Price Chart Analysis
Trend: The stock is currently in a consolidation phase, with potential for an upward breakout.
Target Levels: ₹674.45, ₹728.95, ₹798.35, ₹998.75
Key Levels:
Primary Support Zone (Yellow): ₹419- ₹473
Reversal Zone (Green): ₹521.30 - ₹550.00
Technical Indicators
Relative Strength Index (RSI): 44.09 (Neutral momentum)
Volume: 5.41M
Key Observations
Volume: 5.41M
Timeframe: Weekly
The stock is trading within a consolidation phase, suggesting potential for an upward breakout.
The RSI indicates neutral momentum, suggesting that the stock is neither overbought nor oversold.
The volume indicates a healthy level of trading activity, supporting the current price movement.
Earnings Overview
Q3 FY25 Net Profit: ₹120 crore
Q3 FY24 Net Profit: ₹80 crore
Revenue Growth: 20% increase to ₹1,500 crore
Key Highlights:
KIMS reported a net profit of ₹120 crore in Q3 FY25, compared to ₹80 crore in the same quarter last year.
The company's revenue surged by 20%, driven by strong performance across its healthcare segments.
KIMS continues to focus on expanding its medical services and enhancing patient care, positively impacting its financial performance.
Conclusion
Krishna Institute of Medical Sciences Ltd. is showing signs of potential upward movement, with key resistance levels ahead. The neutral RSI suggests that there is room for further upward movement without immediate risk of overbought conditions. Investors should watch for potential breakouts above the resistance levels and monitor the support zones for any signs of reversal.
Krishna Institute of Medical Sciences (KIMS) is a prominent healthcare provider in India, offering a wide range of medical services across various specialties. KIMS is known for its state-of-the-art facilities, experienced medical professionals, and commitment to delivering quality healthcare. With multiple hospitals and centers, KIMS aims to provide accessible and affordable healthcare services to the community.
Price Chart Analysis
Trend: The stock is currently in a consolidation phase, with potential for an upward breakout.
Target Levels: ₹674.45, ₹728.95, ₹798.35, ₹998.75
Key Levels:
Primary Support Zone (Yellow): ₹419- ₹473
Reversal Zone (Green): ₹521.30 - ₹550.00
Technical Indicators
Relative Strength Index (RSI): 44.09 (Neutral momentum)
Volume: 5.41M
Key Observations
Volume: 5.41M
Timeframe: Weekly
The stock is trading within a consolidation phase, suggesting potential for an upward breakout.
The RSI indicates neutral momentum, suggesting that the stock is neither overbought nor oversold.
The volume indicates a healthy level of trading activity, supporting the current price movement.
Earnings Overview
Q3 FY25 Net Profit: ₹120 crore
Q3 FY24 Net Profit: ₹80 crore
Revenue Growth: 20% increase to ₹1,500 crore
Key Highlights:
KIMS reported a net profit of ₹120 crore in Q3 FY25, compared to ₹80 crore in the same quarter last year.
The company's revenue surged by 20%, driven by strong performance across its healthcare segments.
KIMS continues to focus on expanding its medical services and enhancing patient care, positively impacting its financial performance.
Conclusion
Krishna Institute of Medical Sciences Ltd. is showing signs of potential upward movement, with key resistance levels ahead. The neutral RSI suggests that there is room for further upward movement without immediate risk of overbought conditions. Investors should watch for potential breakouts above the resistance levels and monitor the support zones for any signs of reversal.
Trade active
up 10% this week, if you have this position i will recommend book profits and again add at lower levels
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.